{"organizations": [], "uuid": "5cb01e657f240de17f765e5fd20fb4b94fac2057", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-solid-biosciences-provides-update/brief-solid-biosciences-provides-update-on-sgt-001-clinical-development-program-for-duchenne-muscular-dystrophy-idUSASC09W9E", "country": "US", "domain_rank": 408, "title": "BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T14:34:00.000+03:00", "replies_count": 0, "uuid": "5cb01e657f240de17f765e5fd20fb4b94fac2057"}, "author": "", "url": "https://www.reuters.com/article/brief-solid-biosciences-provides-update/brief-solid-biosciences-provides-update-on-sgt-001-clinical-development-program-for-duchenne-muscular-dystrophy-idUSASC09W9E", "ord_in_thread": 0, "title": "BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-solid biosciences", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "duchenne muscular dystrophy reuters staff    solid biosciences inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 35 AM / Updated 23 minutes ago BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy Reuters Staff \n  Solid Biosciences Inc: \n* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY \n* SOLID BIOSCIENCES INC - FULL CLINICAL HOLD LETTER FROM FDA RECEIVED; COMPANY TO RESPOND IN COMING WEEKS \n* SOLID BIOSCIENCES INC - MANUFACTURING-RELATED PARTIAL CLINICAL HOLD ON HIGH DOSE OF SGT-001 RESOLVED \n* SOLID BIOSCIENCES - GOT LETTER FROM U.S. FDA RELATING TO PREVIOUSLY-ANNOUNCED FULL CLINICAL HOLD ON IGNITE DMD TRIAL \n* SOLID BIOSCIENCES - FULL CLINICAL HOLD WAS IN RESPONSE TO COâ€™S REPORT OF A SERIOUS ADVERSE EVENT IN FIRST PATIENT DOSED WITH SGT-001 IN IGNITE DMD \n* SOLID BIOSCIENCES - FDA SAYS CO ADDRESSED MANUFACTURING-RELATED QUESTIONS LEADING TO PARTIAL CLINICAL HOLD ON HIGH DOSE OF SGT-001 IN IGNITE DMD Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-18T14:34:00.000+03:00", "crawled": "2018-04-18T15:00:25.000+03:00", "highlightTitle": ""}